NCT02513771 - Sitagliptin for Reducing Inflammation and Immune Activation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 13, 2016

Study Completion Date

January 10, 2017

Conditions

HIV-1 Infection

Interventions

DRUG

Sitagliptin

100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up

DRUG

Placebo for sitagliptin

One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.

Trial Locations (16)

10011

Cornell CRS (7804), New York

10032

Columbia Physicians and Surgeons CRS (30329), New York

14642

University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester

15213

Pittsburgh CRS (1001), Pittsburgh

19104

Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia

20009

Whitman Walker Health CRS (31791), Washington D.C.

27401

Greensboro CRS (3203), Greensboro

27516

Unc Aids Crs (3201), Chapel Hill

43210

The Ohio State Univ. AIDS CRS (2301), Columbus

44106

Case CRS (2501), Cleveland

45267

Univ. of Cincinnati CRS (2401), Cincinnati

63110

Washington University CRS (2101), St Louis

77030

Houston AIDS Research Team CRS (31473), Houston

90095

UCLA CARE Center CRS (601), Los Angeles

90502

Harbor-UCLA Med. Ctr. CRS (603), Torrance

90033-1079

University of Southern California (1201), Los Angeles

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK